Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-519 MAD Study in Healthy Volunteers
NCT02753504Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rocacetrapib in dyslipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 14, Area Under the Curve to Last Measurable Concentration at Steady State at Day 14 and 5 more. Started Apr 2016; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02753504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753504.